MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas
  
commercial bribery
MetaVia shareholders and analysts disagree on prospects for obesity drug DA-1726 (Shutterstock)

More from Strategy

More from Therapy Areas